Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-02-15
2011-02-15
Zhou, Shubo (Joe) (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S388100, C435S007800, C435S230000
Reexamination Certificate
active
07888477
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.
REFERENCES:
patent: 5480795 (1996-01-01), Kurihara et al.
patent: 6284487 (2001-09-01), Stahl et al.
patent: 1033401 (2000-09-01), None
patent: WO 99/25877 (1999-05-01), None
patent: WO 99/31117 (1999-06-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 00/12758 (2000-03-01), None
patent: WO 00/36107 (2000-06-01), None
patent: WO 00/55629 (2000-09-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 00/76531 (2000-12-01), None
patent: WO 01/16318 (2001-03-01), None
patent: WO 01/18542 (2001-03-01), None
patent: WO 01/40269 (2001-06-01), None
patent: WO 01/57272 (2001-08-01), None
patent: WO 01/94641 (2001-12-01), None
patent: WO 02/02587 (2002-01-01), None
patent: WO 02/02624 (2002-01-01), None
patent: WO 02/10187 (2002-02-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/16581 (2002-02-01), None
Bookman et al., “Biological therapy of ovarian cancer: Current directions,”Seminars in Oncology, 25(3):381-396, 1998.
Frankel, A.E. et al., “Targeted Toxins,”Clinical Cancer Research6 : 326-334, Feb. 2000.
GenBank Database, Accession No. AA075632, Dec. 23, 1997. Available at www.ncbi.nlm.nih.gov/entrz.
GenBank Database, Accession No. AA404225, Aug. 8, 1997. Available at www.ncbi.nlm.nih.gov/entrz.
GenBank Database, Accession No. U97694, Aug. 27, 1997. Available at www.ncbi.nlm.nih.gov/entrz.
Geneseq Database (Thomson Derwent), Accession No. AAT23436, Aug. 8, 1996.
Gillespie et al., “Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue,”British Journal of Cancer, 78(6):816-821, Sep. 1998.
Heller et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays,”Proc. Natl. Acad. Sci. USA94:2150-2155, Mar. 1997.
Hovig, E. et al., “CA 125: The End of the Beginning,”Tumor Biology22: 345-347, 2001.
Ishikawa et al., “Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins in vitro,”DNA Res., 5:169-176, 1998.
Jin et al., “Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1,”Cell 93:81-91, Apr. 3, 1998.
Köhler et al., “Immunotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125—Results of the Phase LB Study,”Gebrutshilfe and Fraenheilkunde, 58(4):180-186, Apr. 1998 + (English Abstract).
Ma et al., “Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses,”Journal of Pharmaceutical Sciences, 87(11):1375-1378, Nov. 1998.
O'Brien, T.J. et al., “The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure,”Tumor Biology23: 154-169, 2002.
O'Brien, T.J. et al., “The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences,”Tumor Biology22: 348-366, 2001.
Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,”The Journal of Immunology152(1):163-175, Jan. 1, 1994.
Peoples et al., “Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides,”Annals of Surgical Oncology, 5(8):743-750, Dec. 1998.
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,”Proc. Natl. Acad. Sci., 93:10614-10619, Oct. 1996.
Schummer, M. et al., “Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,”Gene238: 375-385, 1999.
Whitehouse, C. et al., “NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube,”Eur. J. Biochem.269: 538-545, 2002.
Yin and Lloyd, “Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16,”Journal of Biological Chemistry276 (29): 27371-27375, Jul. 20, 2001.
Yin, B.W.T. et al., “Ovarian cancer antigen CA125 is encoded by theMUC16mucin gene,”International Journal of Cancer98: 737-740, 2002.
Durbaka et al., “B7S1, a Novel B7 Family Member That Negatively Regulates T Cell Activation,” Immunity 18(6): 863-873, Jun. 1, 2003.
Salceda et al., “The Immunomodulatory Protein B7-H4 is Overexpressed in Breast and Ovarian Cancers and Promotes Epithelial Cell Transformation,” Experimental Cell Research 306(1): 128-141, May 15, 2005.
Sica et al., “B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity,” Immunity 18(6): 849-861, Jun. 1, 2003.
Zang et al., “B7X: A Widely Expressed B7 Family Member That Inhibits T Cell Activation,” Proceedings of the Nat'l Acad. of Sciences 100(18): 10388-10392, Sep. 2, 2003.
Bangur Chaitanya S
Fanger Gary R
Hill Paul
Retter Marc W
Corixa Corporation
Seed IP Law Group PLLC
Zhou Shubo (Joe)
LandOfFree
Ovarian cancer-associated antibodies and kits does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ovarian cancer-associated antibodies and kits, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ovarian cancer-associated antibodies and kits will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623500